SR One-backed gene expression technology developer Constellation Pharmaceuticals has filed for an $86.3m initial public offering.

Constellation Pharmaceuticals, a US-based biopharmaceutical company backed by pharmaceutical firm GlaxoSmithKline, has filed to raise up to $86.3m in an initial public offering on the Nasdaq Global Market.

Founded in 2008, Constellation is applying epigenetics, the study of the modification of gene expression, to develop small-molecule therapies for patients suffering from cancers fuelled by abnormal gene expression or drug resistance.

Part of the IPO proceeds will fund phase 1b/2 clinical trials for the company’s lead drug candidate, CPI-1205, in…